Press Release: Vyant Bio presents key findings from the platform and poster |

CHERRY HILL, NJ, Nov. 10, 2022 (GLOBE NEWSWIRE) — Wyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative diseases. The Company’s central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain diseases, scaled biology and machine learning to identify and validate drug targets and therapeutic candidates. Today, at the 2022 CDKL5 Forum hosted by the Loulou Foundation on November 7, Vyant Bio shared key insights from its platform and poster presentations by Vyant Bio Senior Scientist Matthew Green, Ph.D^th and 8^th, 2022, in Boston, MA. Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) is a rare neurodevelopmental disorder caused by pathogenic mutations in the CDKL5 Gen. Common symptoms include early-onset, difficult-to-control seizures and…